Literature DB >> 2989829

Beta 2-adrenergic receptors contribute to catecholamine-stimulated shortening of action potential duration in dog atrial muscle.

B T Liang, L H Frame, P B Molinoff.   

Abstract

beta 1- and beta 2-adrenergic receptors coexist in atria of humans and a variety of other species. The significance of these receptors and the quantitative extent to which beta 2-adrenergic receptors contribute to the electrophysiologic effects of catecholamines acting at beta-adrenergic receptors have not been determined. In the present study, the beta 1-selective antagonist ICI 89,406 and the beta 2-selective antagonist ICI 118,551 were used to determine the relative densities of beta 1- and beta 2-adrenergic receptors on membranes prepared from dog atria and the contribution that each subtype makes to isoproterenol-induced shortening of action potential duration measured at 75% repolarization (APD75). Computer-aided nonlinear regression analysis of the inhibition of the specific binding of [125I]iodopindolol and the inhibition of isoproterenol-stimulated APD75 shortening by these antagonists showed that a two-site model fits the data better than a one-site model (P less than 0.0001). The affinity constants for each selective antagonist determined by inhibition of APD75 shortening were similar to those determined in studies of the inhibition of the specific binding of [125I]iodopindolol to beta 1- and beta 2-adrenergic receptors. beta 2-Adrenergic receptors made up approximately equal to 25% of the total number of beta-adrenergic receptors but mediated approximately equal to 50% of the electrophysiologic effect of isoproterenol. The inhibition of the binding of [125I]iodopindolol and of the APD75 shortening by propranolol, a nonselective antagonist, was best fit by a one-site model. In other experiments, dogs were treated with reserpine and atropine to eliminate complications caused by the presence of endogenous norepinephrine and acetylcholine. Results obtained with atria from these animals were similar to those obtained in studies with control atria. These data suggest that beta 2-adrenergic receptors as well as beta 1-adrenergic receptors are involved in mediating the electrophysiologic effects of catecholamines in dog atrial muscle and that both beta 1- and beta 2-adrenergic receptors are present on atrial muscle cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989829      PMCID: PMC391134          DOI: 10.1073/pnas.82.13.4521

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Binding of iodinated beta adrenergic antagonists to proteins derived from rat heart.

Authors:  T K Harden; B B Wolfe; P B Molinoff
Journal:  Mol Pharmacol       Date:  1976-01       Impact factor: 4.436

2.  Pharmacological studies of OPC-2009, a newly synthesized selective beta adrenoceptor stimulant, in the broncho-motor and cardiovascular system of the anesthetized dog.

Authors:  Y Yabuuchi; S Yamashita; S S Tei
Journal:  J Pharmacol Exp Ther       Date:  1977-08       Impact factor: 4.030

3.  Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart.

Authors:  A Hedberg; K P Minneman; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1980-03       Impact factor: 4.030

Review 4.  Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part A.

Authors:  A L Wit; B F Hoffman; M R Rosen
Journal:  Am Heart J       Date:  1975-10       Impact factor: 4.749

5.  Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes.

Authors:  K P Minneman; L R Hegstrand; P B Molinoff
Journal:  Mol Pharmacol       Date:  1979-07       Impact factor: 4.436

6.  Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.

Authors:  E Carlsson; C G Dahlöf; A Hedberg; H Persson; B Tångstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

7.  New high performance liquid chromatographic analysis of brain catecholamines.

Authors:  C Refshauge; P T Kissinger; R Dreiling; L Blank; R Freeman; R N Adams
Journal:  Life Sci       Date:  1974-01-16       Impact factor: 5.037

8.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

9.  Binding of (125I)iodohydroxybenzylpindolol to putative beta-adrenergic receptors of rat glioma cells and other cell clones.

Authors:  M E Maguire; R A Wiklund; H J Anderson; A G Gilman
Journal:  J Biol Chem       Date:  1976-03-10       Impact factor: 5.157

10.  Beta-adrenergic receptor: stereospecific interaction of iodinated beta-blocking agent with high affinity site.

Authors:  G D Aurbach; S A Fedak; C J Woodard; J S Palmer; D Hauser; F Troxler
Journal:  Science       Date:  1974-12-27       Impact factor: 47.728

View more
  4 in total

1.  Atrial tachyarrhythmias induced by the combined effects of β1/2-adrenergic autoantibodies and thyroid hormone in the rabbit.

Authors:  Hongliang Li; Benjamin J Scherlag; David C Kem; Alexandria Benbrook; Ling Zhang; Bing Huang; Madeleine W Cunningham; Ralph Lazzara; Xichun Yu
Journal:  J Cardiovasc Transl Res       Date:  2014-06-06       Impact factor: 4.132

2.  Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.

Authors:  M D Lowe; E Rowland; M J Brown; A A Grace
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

3.  Pharmacological Tests in Atrial Fibrillation Ablation.

Authors:  Jean-Baptiste Gourraud; Jason G Andrade; Laurent Macle; Blandine Mondésert
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

Review 4.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.